Erratum: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel (Oncotarget (2018) 9 (31985-31998) DOI: 10.18632/oncotarget.25868)

Manabu Seino, Tsuyoshi Ohta, Akiko Sugiyama, Hirotsugu Sakaki, Takeshi Sudo, Seiji Tsutsumi, Shogo Shigeta, Hideki Tokunaga, Masafumi Toyoshima, Nobuo Yaegashi, Satoru Nagase

Research output: Contribution to journalComment/debatepeer-review

Abstract

This article has been corrected: Due to errors during figure preparation, Figure 5 was marked and labeled incorrectly. Specifically, the value of cysteine has been corrected in the first column of the box labeled 'Cys' in Figure 5B (USPC-1 Control). Lines and asterisks denoting comparisons between groups were also added to this box. X-axis lines were added to all boxes in 5B, along with concentration units on the Y axis. The color key used in 5A has also been added to 5B. The proper Figure 5 is shown below. In addition, the information for affiliation 2 is listed incorrectly; the proper affiliation is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure Presented).

Original languageEnglish
Pages (from-to)2321
Number of pages1
JournalOncotarget
Volume12
Issue number23
DOIs
Publication statusPublished - 2021 Nov 9

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Erratum: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel (Oncotarget (2018) 9 (31985-31998) DOI: 10.18632/oncotarget.25868)'. Together they form a unique fingerprint.

Cite this